Advanced breast cancer treatments are entering a precision medicine era where targeted therapies can transform outcomes for patients with historically poor prognoses. Triple-negative breast cancer represents one of the most challenging subtypes, lacking the hormone receptors and HER2 proteins that make other breast cancers responsive to established therapies. Sacituzumab govitecan represents a novel antibody-drug conjugate approach that delivers cytotoxic payloads directly to cancer cells through targeted binding mechanisms. This therapeutic strategy combines the specificity of monoclonal antibodies with the cell-killing power of chemotherapy agents, potentially reducing systemic toxicity while maximizing tumor destruction. The treatment targets Trop-2, a cell surface glycoprotein highly expressed in triple-negative breast cancer cells, acting as a molecular delivery system for the topoisomerase inhibitor payload. This mechanism allows concentrated drug delivery to malignant tissue while sparing healthy cells that express lower levels of the target protein. The antibody-drug conjugate field represents a significant evolution in oncology therapeutics, moving beyond traditional chemotherapy's broad cellular toxicity toward precision targeting. For triple-negative breast cancer patients, who historically faced limited treatment options and aggressive disease progression, such targeted approaches offer meaningful hope for improved survival outcomes. However, the complexity of antibody-drug conjugates requires careful patient selection and monitoring for unique toxicity profiles that differ from conventional chemotherapy. The success of this approach may influence broader cancer treatment paradigms and accelerate development of similar conjugate therapies across multiple tumor types.